Kanghong has developed a market of over 2 billion!

Recently, Kanghong Pharmaceutical issued an announcement that the company has been approved for imitation of pramipexole hydrochloride sustained-release tablets for production in four categories, and is deemed to have been reviewed
.

Basic drug information

Pramipexole, developed by Boehringer Ingelheim, is a new generation of non-ergotamine dopamine receptor agonists.
It relieves dyskinesia in patients with Parkinson's disease by exciting the dopamine receptors in the striatum and is used to treat adult idiopathic Parkinson's.
Signs and symptoms of the disease
.

According to data from Meinenet, in recent years, the sales of terminal anti-Parkinson's drugs in urban public hospitals, county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have grown rapidly, breaking the 2 billion mark in 2019.
, It will reach a new high in 2020, with a year-on-year growth of more than 15%
.

TOP10 Generic Names of Anti-Parkinson's Disease Drugs in China's Public Medical Institutions in 2020

Source: Mi Nei.
com, China's public medical institutions terminal competition pattern

There are pramipexole hydrochloride tablets and pramipexole hydrochloride sustained-release tablets.
At present, there are 9 manufacturers of pramipexole hydrochloride sustained-release tablets, including Jiangsu Hengrui Pharmaceutical, Qilu Pharmaceutical (Hainan), and Tianjin Hongri Pharmaceutical Eight domestic pharmaceutical companies, including Chengdu Kanghong Pharmaceutical and Chengdu Kanghong Pharmaceutical, have been approved for imitation of category 4 as over-reviewed
.

Kanghong Pharmaceutical said that the approval of pramipexole hydrochloride sustained-release tablets has enriched the company's product pipeline in the central nervous field, which will help enhance the company's market competitiveness and will have a positive impact on the company's pharmaceutical business